Haloperidol-Associated Uterine Dystonia
Publication: American Journal of Psychiatry
To the Editor: Haloperidol is a first-generation antipsychotic recommended for psychosis in pregnancy (1). Up to 60% of patients on first-generation antipsychotics develop an acute dystonia (2). Haloperidol could induce uterine or fetal dystonia (3), although this has not been previously reported. We report the case of a pregnant 27-year-old woman who experienced uterine dystonia associated with haloperidol:
A 27-year-old woman presented during her second pregnancy at 25 weeks’ gestation. She had a history of depressive disorder (unspecified) and anxiety disorder (unspecified) and was admitted for depression. At admission she was taking clonazepam only. Clonazepam was discontinued, and on admission day, she was administered 5 mg of haloperidol as needed for anxiety or agitation. Prior to this hospitalization, the patient was antipsychotic-naive and received nine doses over 3 days. On admission day 4, 2 hours after taking haloperidol, she developed cervical and limb dystonia, uterine contractions lasting 30–45 seconds spaced 10 minutes apart, and increased fetal movements. Uterine tone was moderate. Treatment with 2 mg of benztropine partially improved the cervical and limb dystonia; she continued to report contractions. After receiving 50 mg of diphenhydramine and 1 mg of benztropine, she was sent for emergent obstetric evaluation. Her cervical and limb dystonia resolved, contractions continued at the same rate, and increased fetal movements were noted. Contractions stopped 10 hours later; fetal status was reassuring. She was discharged for continued psychiatric management.
Haloperidol is a D2 antagonist associated with adverse obstetric and neonatal outcomes (4) that may potentiate uterine contractility (5). D2 antagonists increase oxytocin release (6), and haloperidol enhances adenosine receptor function during uterine muscle contraction (7). In addition, haloperidol modulates intracellular calcium pathways associated with myometrial contractility (8). Haloperidol crosses the placenta and is detectable in newborns of mothers taking haloperidol (3). Newborns exposed to antipsychotics in the third trimester are at risk for extrapyramidal symptoms (9); similar symptoms could occur in utero. This case illustrates a potential complication of haloperidol with pregnancy and suggests the need for further research regarding this potential side effect.
References
1.
Chisolm MS, Payne JL: Management of psychotropic drugs during pregnancy. BMJ 2016; 532:h5918
2.
Burkhard PR: Acute and subacute drug-induced movement disorders. Parkinsonism Relat Disord 2014; 20(Suppl 1):S108–S112
3.
Uematsu T, Yamada K, Matsuno H, et al: The measurement of haloperidol and reduced haloperidol in neonatal hair as an index of placental transfer of maternal haloperidol. Ther Drug Monit 1991; 13:183–187
4.
Coughlin CG, Blackwell KA, Bartley C, et al: Obstetric and neonatal outcomes after antipsychotic medication exposure in pregnancy. Obstet Gynecol 2015; 125:1224–1235
5.
Voltolini C, Torricelli M, Conti N, et al: Understanding spontaneous preterm birth: from underlying mechanisms to predictive and preventive interventions. Reprod Sci 2013; 20:1274–1292
6.
Crowley WR, Parker SL, Armstrong WE, et al: Excitatory and inhibitory dopaminergic regulation of oxytocin secretion in the lactating rat: evidence for respective mediation by D-1 and D-2 dopamine receptor subtypes. Neuroendocrinology 1991; 53:493–502
7.
Trincavelli ML, Cuboni S, Catena Dell’osso M, et al: Receptor crosstalk: haloperidol treatment enhances A(2A) adenosine receptor functioning in a transfected cell model. Purinergic Signal 2010; 6:373–381
8.
Al Otaibi M: The physiological mechanism of uterine contraction with emphasis on calcium ion. Calcium Signal (St Clara) 2014; 1:70–75
9.
US Food and Drug Administration (FDA): FDA Drug Safety Communication: Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns. Silver Spring, Md, FDA, Feb 22, 2011. http://www.fda.gov/Drugs/DrugSafety/ucm243903.htm
Information & Authors
Information
Published In
History
Accepted: December 2016
Published online: 1 March 2017
Published in print: March 01, 2017
Keywords
Authors
Funding Information
National Institute of Mental Health10.13039/100000025: R25 MH101076
The authors report no financial relationships with commercial interests.Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
There are no citations for this item
View Options
View options
PDF/ePub
View PDF/ePubGet Access
Login options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).